Phoenix 8.0

Phoenix 8.0

Phoenix PK/PD Modeling and Simulation Software Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with an easy-to-use graphical user interface and the additional tools needed to support more advanced analysis, such as population PK/PD modeling with Phoenix NLME and in vitro-in vivo correlation with the IVIVC Toolkit. The Phoenix Workbench leverages […]

Read More
Topics:

Phoenix WinNonlin

Phoenix WinNonlin: The Industry Standard for NCA and PK/PD Modeling and Simulation Phoenix® WinNonlin® is the industry standard for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling. Integrated tools for data processing, post-analysis processing, table creation, and graphics create an all-in-one collaboration workbench used by scientists, reviewers, medical writers, and quality assurance staff for drug […]

Read More
Topics:

PK/PD Modeling and Simulation

Phoenix: The Most Advanced, Intuitive, and Widely-used Software for Pharmacokinetic (PK), Pharmacodynamic (PD), and Toxicokinetic (TK) Modeling and Simulation Phoenix®, the industry’s premier PK/PD modeling and simulation software workbench, is used by over 6,000 scientists in 60 countries at nearly 2,000 institutions, including the top 50 global pharmaceutical companies. Regulatory agencies, including 11 divisions of the US […]

Read More
Topics:

Contact Us

Sales Inquiries Interested in learning more? Please fill out the form and a representative will get back to you. Or, please contact us at any of our locations below: United States:  1-888-708-7444 or 1-919-852-4685 France:  +33 1 56 95 17 10 Germany:  +49 89 45 10 300 United Kingdom:  +44 (0) 114 292 2322 Australia:  +61 […]

Read More
Topics:

About Our Solutions

Cutting Edge Modeling and Simulation Solutions for Drug Development Drug development has become more complex and multi-layered.  New combination therapies require more precise and individualized analyses, new approaches such as “basket studies” evaluate potential disease targets through a new lens, safety issues are more challenging, and comparative effectiveness plays an increasingly important role in “go/no […]

Read More
Topics:
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog